Altimmune

Peptide therapeutics (obesity/liver disease)

ALT · Nasdaq · United States

Share price · ALT

$1.39-1.58 (-53.20%) 3M

close as of 2026-11-18 · 24h delayed · vol 4.7M (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ALT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026-9.2%
  2. 12 Nov 2026-16.6%
  3. 10 Nov 2026-8.5%
  4. 14 Oct 2026-4.9%
  5. 24 Sep 2026-4.7%
  6. 4 Sep 2026+5.9%
  7. 2 Sep 2026+6.1%
  8. 3 Aug 2026+5.6%
  9. 27 Jul 2026+6.9%

    Nothing announced by ALT that day or the session before.

  10. 1 May 2026+8.5%

Share of unusual movement by asset

For each asset, the share of ALT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
pemvidutide
events and moves
1132%
Other company news (earnings, financing, releases naming no asset)—24%
Sessions with no dated event—45%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
GLP-1/glucagon receptor (dual)Peptide
MASH / NASH

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
pemvidutidePhase 2Alcohol-associated Liver Disease
Est. primary completion 2027-09-30 · NCT07009860 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
pemvidutidePhase 3Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Est. primary completion 2028-12 · NCT07795164 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 July 2026Topline resultpemvidutidePhase 2 RECLAIM of pemvidutide in alcohol use disorder met its primary endpoint
Altimmune · Source ↗
26 June 2025Topline resultpemvidutideIMPACT Phase 2b meets primary endpoint of MASH resolution
Altimmune · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$27M$29M+ $236M short-term inv.$32M-$38M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$19M$63M+ $263M short-term inv.$23M-$24M operating cash flowreport ↗
2026-Q1—$16M$98M+ $234M short-term inv.$23M-$21M operating cash flowreport ↗
2025-Q3<$0.1M$15M$61M+ $150M short-term inv.$19M-$12M operating cash flowreport ↗
2025-Q2<$0.1M$17M$183M$22M-$19M operating cash flowreport ↗
2025-Q1<$0.1M$16M$49M+ $101M short-term inv.$20M-$17M operating cash flowreport ↗
2024-Q3<$0.1M$20M$32M+ $108M short-term inv.$23M-$27M operating cash flowreport ↗
2024-Q2<$0.1M$21M$57M+ $108M short-term inv.$25M-$18M operating cash flowreport ↗
2024-Q1<$0.1M$21M$79M+ $103M short-term inv.$24M-$16M operating cash flowreport ↗
2023-Q3$0.4M$18M$87M+ $54M short-term inv.$21M-$20M operating cash flowreport ↗
2023-Q2<$0.1M$13M$102M+ $58M short-term inv.$16M-$19M operating cash flowreport ↗
2023-Q1<$0.1M$17M$105M+ $61M short-term inv.$20M-$19M operating cash flowreport ↗
2022-Q3$0$20M$128M+ $74M short-term inv.$24M-$15M operating cash flowreport ↗
2022-Q2<$0.1M$16M$136M+ $49M short-term inv.$20M-$17M operating cash flowreport ↗
2022-Q1<$0.1M$15M$180M$19M-$14M operating cash flowreport ↗
2021-Q3—$29M$175M+ $25M short-term inv.$34M-$18M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY<$0.1M$66M$44M+ $230M short-term inv.$22M-$68M operating cash flowreport ↗

For the full year 2025, Altimmune reported revenue of $0.04M, up 100.0% YoY, with R&D spend of $66.43M, down 19.2% YoY. Cash and equivalents were $43.8M, and the company reported a net loss of $88.09M.

The company plans to initiate a Phase 3 MASH trial in 2026 and received FDA Breakthrough Therapy Designation for pemvidutide in MASH, with topline data from the Phase 2 RECLAIM trial in alcohol use disorder expected in Q3 2026. The Phase 2 RESTORE trial in alcohol-associated liver disease is enrolling, Jerry Durso was appointed CEO, and the balance sheet was strengthened through a $75M registered direct offering in January 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY<$0.1M$82M$37M+ $95M short-term inv.$24M-$80M operating cash flowreport ↗
2023-FY$0.4M$66M$135M+ $63M short-term inv.$22M-$76M operating cash flowreport ↗
2022-FY-$0.1M$71M$111M+ $74M short-term inv.$21M-$63M operating cash flowreport ↗
2021-FY$4.4M$75M$190M$24M-$78M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 15 purchases ($466K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-18MENZIUSO RICHARD THOMAS · Principal Accounting OfficerOpen-market purchase10,000$1.42$14KForm 4
2026-11-13Durso Jerome Benedict · director, President and CEOOpen-market purchase30,700$1.62$50KForm 4
2026-11-13Pisano Wayne · directorOpen-market purchase10,000$1.64$16KForm 4
2026-11-13WEAVER GREGORY L · Chief Financial OfficerOpen-market purchase10,000$1.62$16KForm 4
2026-11-11WEAVER GREGORY L · Chief Financial OfficerOption exercise18,750——Form 4
2026-11-11WEAVER GREGORY L · Chief Financial OfficerTax withholding5,672$1.93$11KForm 4
2026-11-11WEAVER GREGORY L · Chief Financial OfficerOption exercise (derivative)18,750——Form 4
2026-11-02Howarth Alex G. · directorAward / grant (derivative)160,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 171 reporting institutions held 69.3M shares ($212.1M, 35.6% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.12,795,277$39.4M
2STATE STREET CORP7,145,550$22.0M
3VANGUARD CAPITAL MANAGEMENT LLC5,658,049$17.4M
4VANGUARD PORTFOLIO MANAGEMENT LLC5,382,002$16.6M
5MARSHALL WACE, LLP4,017,901$12.4M
6MILLENNIUM MANAGEMENT LLC3,258,191$10.0M
7GEODE CAPITAL MANAGEMENT, LLC3,107,096$9.6M
8Alyeska Investment Group, L.P.2,644,600$8.1M
9TWO SIGMA INVESTMENTS, LP2,478,900$7.6M
10Nuveen, LLC2,334,601$7.2M
11GOLDMAN SACHS GROUP INC1,350,649$4.2M
12SUSQUEHANNA INTERNATIONAL GROUP, LLP1,325,956$4.1M
13DIMENSIONAL FUND ADVISORS LP1,045,926$3.2M
14NORTHERN TRUST CORP996,721$3.1M
15UBS Group AG904,768$2.8M